Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

Abstract This single‐center, open‐label, non‐randomized, two‐part, phase I study was conducted (1) to evaluate the absolute oral bioavailability of rilzabrutinib 400 mg tablet following an i.v. microtracer dose of ~100 μg [14C]‐rilzabrutinib (~1 μCi) and single oral dose of 400 mg rilzabrutinib tabl...

Full description

Bibliographic Details
Main Authors: Sibel Ucpinar, Patrick F. Smith, Li Long, Fujun Li, Hui Yan, Jyoti Wadhwa, Katherine A. Chu, Jin Shu, Philip Nunn, Mengyao Li
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13524

Internet

https://doi.org/10.1111/cts.13524

Similar Items